Safety and efficacy of immunotherapy using a double-dose regimen in advanced non-small cell lung cancer (NSCLC): results of IDEE study.

Clémence PierreYannick Le GuenCaroline GiordanengoThomas GoterHervé LénaClémence NielGonzague De ChabotMarie TiercinGwenaelle Le GarffFrançois ZimmermannQuentin Le CornuCharles Ricordel

Published in: Translational lung cancer research (2024)

Our multicentric cohort supports the feasibility of pembrolizumab Q6W and nivolumab Q4W for patients with advanced NSCLC. There is no warning signal regarding safety neither efficacy in our real-life data.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
small cell lung cancer
big data
machine learning
artificial intelligence
deep learning